Eribulin Ever Pharma

Eribulin Mesylate is a chemotherapy medication used to treat certain types of cancer. This intravenous drug is manufactured by Ever Valinject GmbH and is available in the EU market.

Eribulin Mesylate is primarily used in the treatment of advanced breast cancer and liposarcoma. It works by interfering with the growth and spread of cancer cells. Patients often wonder, 'What is Eribulin Mesylate used for?' and it is typically prescribed for metastatic breast cancer that has progressed after other treatments.

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may experience peripheral neuropathy, which can cause numbness or tingling in the hands and feet. These effects can vary from person to person.

Eribulin Mesylate should be handled with care and administered by healthcare professionals. It is important to follow all safety guidelines when using this medication. Patients should discuss any pre-existing conditions or medications with their healthcare provider before starting treatment.

Eribulin Mesylate may interact with other medications, including those that affect the liver or bone marrow. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of Eribulin Mesylate.